Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 25, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 340,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,474.126 pence per share.
- Treasury Shares Held: 166,639,678 shares (post-transaction).
- Shares in Issue: 5,815,385,085 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 340,000 shares on May 25, 2006. These shares are intended to be held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 340,000 share repurchase based on the disclosed price of 1,474.126 pence per share.
- Confirm the updated total share count (5,815,385,085 in issue) against subsequent filings to track ongoing buyback activity.
- Note that this filing is a notification of a specific transaction and does not replace periodic financial reports (Form 20-F) for comprehensive performance analysis.